Lilly plans $72 million investment in insulin manufacturing

| By | Drug Manufacturing, Eli Lilly and Company, Investments

Eli Lilly and Company today announced plans to invest $72 million in an insulin manufacturing project at one of its facilities in Indianapolis, USA.

The investment will be used to replace an existing insulin vial filling line and allow Lilly to meet growing demand for its insulins – including Humalog® (insulin lispro) and Humulin® (human insulin) – while upgrading to state-of-the-art technology and preparing for its insulin pipeline.

Insulin is a core element of Lilly’s diabetes business, and its U.S. manufacturing operations are an integral part of insulin supply. Lilly has a nine-decade legacy of researching and producing insulin, and the Indianapolis manufacturing facility plays a significant role in the process. Replacing the existing line will allow for the installation of a new insulin vial filling line that aligns with modern design expectations and utilizes state-of-the-art technology.

“As technology and science continually advance, it is important that our manufacturing facilities are recapitalized and modernized regularly to ensure we can continue to provide a reliable supply of safe and high-quality medicines to people around the world,” said Maria Crowe, president of Lilly Global Manufacturing Operations.

SOURCE: eli lilly
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.